Page not found

Page not found

We want to help you find what you are looking for

We’re sorry, but the page you tried to find may have moved or is no longer available. Browse through the links in the site map below.

IMPORTANT SAFETY INFORMATION

Contraindications: Known hypersensitivity to QUZYTTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Additional Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving or operating potentially dangerous machinery. Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.

Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.

The most common adverse reactions (incidence ≥2%) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting.

For more information, please see the full Prescribing Information for QUZYTTIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You can also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

INDICATIONS AND USAGE

QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.

Limitations of Use: QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

Important Safety Information and Indication

IMPORTANT SAFETY INFORMATION

Contraindications: Known hypersensitivity to QUZYTTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.

For more information, please see the full Prescribing Information for QUZYTTIR.

INDICATIONS AND USAGE

QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.

Limitations of Use: QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

Reference

QUZYTTIR (cetirizine hydrochloride injection) [package insert]. Deerfield, IL: TerSera Therapeutics LLC; 2020.

References

QUZYTTIR (cetirizine hydrochloride injection) [package insert]. Deerfield, IL: TerSera Therapeutics LLC; 2020.
Abella BS, Berger WE, Blaiss MS, et al. Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: a phase III randomized controlled noninferiority trial. Ann Emerg Med. 2020 Oct;76(4):489-500.
Asthma and Allergy Foundation of America. https://www.aafa.org/hives/. Accessed December 10, 2019.
Sánchez-Borges M, et al. World Allergy Organ J. 2012;5:125-147.

References

QUZYTTIR (cetirizine hydrochloride injection) [package insert]. Deerfield, IL: TerSera Therapeutics LLC; 2020.
Abella BS, Berger WE, Blaiss MS, et al. Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: a phase III randomized controlled noninferiority trial. Ann Emerg Med. 2020 Oct;76(4):489-500.

Reference

QUZYTTIR (cetirizine hydrochloride injection) [package insert]. Deerfield, IL: TerSera Therapeutics LLC; 2020.

References

QUZYTTIR (cetirizine hydrochloride injection) [package insert]. Deerfield, IL: TerSera Therapeutics LLC; 2020.
2019 American Geriatrics Society Beers Criteria^® Update Expert Panel. J Am Geriatr Soc. 2019;67:674-694.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Older Adult Oncology V2.2022. © National Comprehensive Cancer Network, Inc 2021. All rights reserved. Accessed November 15, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK, NCCN^®, NCCN GUIDELINES^®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Winters M. Clinical practice guideline: initial evaluation and management of patients presenting with acute urticaria or angioedema. https://www.aaem.org/resources/statements/position/clinical-practice-guideline-initial-evaluation-and-management-of-patients-presenting-with-acutre-urticaria-or-angioedema. Accessed October 4, 2019.
Bernstein JA, Lang DM, Khan DA. J Allergy Clin Immunol. 2014;133:1270-1277.
Schaefer P. Am Fam Physician. 2017;95:717-724.

Page not found

We want to help you find what you are looking for

Attention